Company
Dimerix Limited
ASX:DXB
Clinical-stage biopharmaceutical company. Its lead candidate DMX-200 (repagermanium, a chemokine receptor CCR2 antagonist given on top of an angiotensin II receptor blocker) is in the Phase 3 ACTION3 trial for focal segmental glomerulosclerosis (FSGS), a rare glomerular disease that causes scarring of the kidney's filtering units and progressive loss of kidney function toward end-stage renal disease. The trial's primary endpoint is reduction in proteinuria, with eGFR decline as a longer-term measure. A second program, DMX-700, targets orphan respiratory and renal indications and is at an earlier stage. The longevity relevance is narrow and indirect: this is rare-disease nephrology, not a geroscience or ageing-biology program. It is relevant to healthspan only insofar as declining kidney filtration is one of the core organ-decline endpoints, and DMX-200 addresses a specific genetic and idiopathic kidney disease rather than age-related renal decline in the general population. No approved products and no revenue from product sales; the company is pre-approval and dependent on trial outcomes and regional licensing partners.
At a glance
- Listing
- ASX:DXB
- Category
- ASX listed
- Headquarters
- Fitzroy, Melbourne, Victoria, Australia (425 Smith St, Fitzroy 3065)
- Market cap
- ~A$144M (A$0.241 per share, 17 July 2026; down ~57% over the prior twelve months)
Thesis
Why it is in this universe
- Category
- ASX listed
- Market
- Australia
- Recent inflection
- 28 April 2026: Dimerix announced completion of an external blinded assessment of ACTION3's statistical assumptions, confirming the study remains powered at greater than 90% to detect a treatment effect on the proteinuria primary endpoint. In the same announcement the company and its commercial partners decided NOT to proceed with the interim analysis that would have supported a US Accelerated Approval filing, citing added cost, extended timelines, the need for additional confirmatory endpoints, and a reduced probability of success on final endpoints. The stated rationale was a changed FSGS regulatory landscape, including FDA confirmation that proteinuria is acceptable for traditional (full) approval and a recent FDA approval of another FSGS therapy on proteinuria. Net effect: a cleaner path to traditional approval, but the loss of a nearer-term accelerated-approval catalyst, consistent with the shares trading around 57% below their level a year earlier.
- Services
- None recorded
- People tracked
- 1
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | ASX |
| Ticker | ASX:DXB |
| Secondary listing | None |
| Market cap | ~A$144M (A$0.241 per share, 17 July 2026; down ~57% over the prior twelve months) |
| Status | Listed and trading |
Get in touch
Contact
- Address
- Fitzroy, Melbourne, Victoria, Australia (425 Smith St, Fitzroy 3065)
- Website
- dimerix.com
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
People
Who variis tracks here (1)
variis does not publish portraits of named individuals without a licence to do so.
Recent inflection
What moved lately
28 April 2026: Dimerix announced completion of an external blinded assessment of ACTION3's statistical assumptions, confirming the study remains powered at greater than 90% to detect a treatment effect on the proteinuria primary endpoint. In the same announcement the company and its commercial partners decided NOT to proceed with the interim analysis that would have supported a US Accelerated Approval filing, citing added cost, extended timelines, the need for additional confirmatory endpoints, and a reduced probability of success on final endpoints. The stated rationale was a changed FSGS regulatory landscape, including FDA confirmation that proteinuria is acceptable for traditional (full) approval and a recent FDA approval of another FSGS therapy on proteinuria. Net effect: a cleaner path to traditional approval, but the loss of a nearer-term accelerated-approval catalyst, consistent with the shares trading around 57% below their level a year earlier.
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- Dimerix - corporate site (HQ address in Fitzroy, Victoria; DMX-200 Phase 3 in FSGS; DMX-700 program) · Dimerix Limited
- Dimerix Limited (ASX:DXB) stock quote - price A$0.241, market cap A$144.10M, actively trading as at 17 July 2026 · StockAnalysis
- Blinded assessment of ACTION3 statistical assumptions complete (28 April 2026) · PR Newswire, via The Manila Times
- ASX announcement: Blinded assessment of ACTION3 statistical assumptions complete, 28 April 2026 (primary source PDF) · Dimerix Limited / ASX
Every entity profile on variis is sourced. Not investment advice.